American Society of Clinical Oncology [pros]
Technology Assessment [hlca]
Breast [bpoc]
Cancer Risk [qnco]
reduction [npop]
strategies [menp]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Objective [inpr]
To [qlco]
Conduct [inbe]
Evidence [ftcn]
Based [ftcn]
Technology Assessment [hlca]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Breast reduction [topp]
Cancer Risk [qnco]
strategies [menp]
Appropriate [qlco]
Broad [spco]
Based [ftcn]
Conventional [qlco]
Clinical [qlco]
practice [menp]
Potential [qlco]
intervention [hlca]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Outcome [ftcn]
Outcome [ftcn]
Interest [menp]
Breast Cancer [neop]
Incidence [qnco]
Breast Cancer [neop]
Specific [qlco]
Survival [acty]
Overall [inpr]
Survival [acty]
Reticular [spco]
Health Benefits [qnco]
Evidence [ftcn]
Comprehensive [qlco]
Form [qlco]
literature review [inpr]
Conduct [inbe]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Following [tmco]
TOPIC [ftcn]
Breast reduction [topp]
Cancer Risk [qnco]
Tamoxifen [orch, phsu]
side effects [ftcn]
toxicity [qlco]
Including [ftcn]
Endometrial Cancer [neop]
Risk [qlco]
Tamoxifen [orch, phsu]
Non-Malignant [qlco]
Diseases [dsyn]
Including [ftcn]
coronary heart disease [dsyn]
Osteoporosis [dsyn]
Decision Making [menp]
Women [popg]
At risk [qlco]
Breast Cancer [neop]
testimony [gora]
Collected [idcn]
Interested [menp]
Party [cnce]
Values [qlco]
More [ftcn]
weight [orga]
GIVEN [cnce]
Publications [inpr, mnob]
randomized [resa]
Trial [resa]
BENEFITS COSTS [qnco]
American Society of Clinical Oncology [pros]
Working Group [popg]
Woman [popg]
Decision [menp]
Breast reduction [topp]
Cancer Risk [qnco]
strategies [menp]
depend [medd]
weight [orga]
Attribute [idcn]
Information [idcn]
Provided [acty]
Cancer [neop]
Non [ftcn]
cancer risks [qnco]
Conclusions [idcn]
Women [popg]
Defined [cnce]
Projected [inpr]
Risk [qlco]
Breast Cancer [neop]
Equal [qlco]
Tamoxifen [orch, phsu]
mg/d [qnco]
{VP} [qnco]
Offered [fndg]
To [qlco]
Risk [qlco]
Premature [tmco]
recommend [idcn]
Raloxifene [orch, phsu]
To [qlco]
Lower [spco]
Risk [qlco]
Breast Cancer [neop]
Clinical setting [spco]
Trial [resa]
Available [ftcn]
Information [idcn]
Raloxifene [orch, phsu]
Currently [tmco]
Reserve [acty]
Approved [qlco]
indication [idcn]
Ta [imft]
PREVENT [phsu]
Bone Loss [patf]
postmenopausal [tmco]
Women [popg]
Conclusions [idcn]
Based [ftcn]
Single [popg]
Agent [chvf]
Drugs [phsu]
Present [qnco]
Time [tmco]
Effect [qlco]
Using [ftcn]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Medications [phsu]
Hormone replacement therapy [topp]
Using [ftcn]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Combination [qlco]
Not [ftcn]
Study [mnob]
Continuing [idcn]
placebo-controlled [resa]
Trial [resa]
Risk Reduction [inbe]
Trial [resa]
Current [tmco]
Issue [fndg]
Concern [idcn]
interventions [hlca]
influential [idcn]
Reticular [spco]
Health Benefit [qnco]
Ta [imft]
Breast reduction [topp]
Cancer Risk [qnco]
Rapidly [qlco]
Evolving [ftcn]
Area [geoa]
This [euka]
Technology Assessment [hlca]
Represent [acty]
ONGOING [idcn]
Process [bpoc]
Exist [cnce]
PLAN [dsyn]
PO [spco]
monitor [hlca]
Review [inpr]
Data [idcn]
To [qlco]
Update [tmco]
recommendations [idcn]
Table [mnob]
summary [inpr]
Conclusions [idcn]
Validation [resa]
Conclusions [idcn]
Working Group [popg]
Evaluated [ftcn]
American Society of Clinical Oncology [pros]
Health Services Research [resa]
Committee [grup]
American Society of Clinical Oncology [pros]
board [medd]
Sponsor [humn]
American Society of Clinical Oncology [pros]
[c] [qnco]
American Society of Clinical Oncology [pros]
